Is it time to incorporate surgery in the treatment of stage IV non-small cell lung cancer? by Hendriks, Lizza E. L. & Dingemans, Anne-Marie C.
 
 
 
Is it time to incorporate surgery in the treatment of
stage IV non-small cell lung cancer?
Citation for published version (APA):
Hendriks, L. E. L., & Dingemans, A-M. C. (2019). Is it time to incorporate surgery in the treatment of stage
IV non-small cell lung cancer? Lung Cancer, 129, 95-97. https://doi.org/10.1016/j.lungcan.2019.01.011
Document status and date:
Published: 01/03/2019
DOI:
10.1016/j.lungcan.2019.01.011
Document Version:
Publisher's PDF, also known as Version of record
Document license:
Taverne
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 05 Jan. 2021
Contents lists available at ScienceDirect
Lung Cancer
journal homepage: www.elsevier.com/locate/lungcan
Editorial
Is it time to incorporate surgery in the treatment of stage IV non-small cell lung cancer?
Oligometastatic disease is an intermediate state between localized
disease and more widespread metastases [1]. Oligometastatic non-small
cell lung cancer (NSCLC) is usually defined as a maximum of three (Eur-
opean Society for Medical Oncology (ESMO)) or five (National Compre-
hensive Cancer Network (NCCN)) metastases [2,3]. There is a biological
rationale to administer local ablative therapy (LAT, with or without LAT of
the metastases), as metastases can arise from both the primary tumor as
well as the metastases; LAT can prevent reseeding from the treated sites
[4,5]. LAT of (synchronous) oligometastases, usually preceded or followed
by systemic anticancer therapy, is mentioned in the ESMO and NCCN
guidelines [2,3]. LAT has gained interest with the increasing availability of
minimally invasive surgery and stereotactic radiotherapy (SRT) combined
with the promising survival described in retrospective series and single
arm/randomized phase II trials [6–9]. Recently, a significant improvement
in overall survival (OS) was reported in a randomized phase II trial when
LAT (surgery and/or SRT) was added to maintenance treatment/ob-
servation in synchronous oligometastatic NSCLC patients responding to
induction systemic treatment. Median OS was 41.2 (LAT) versus 17
months (control) with a hazard ratio (HR) of 0.40, (p=0.017) [8]. De-
spite that in this phase II trial three metastatic sites were allowed, 68% had
only a single metastasis, and 48% had N0-1 disease [10]. On a population-
based level, it is unknown what the benefit is of LAT of the primary tumor.
Therefore, the study of Sun et al. [11] published in this issue of Lung
Cancer, is of interest.
The authors used the US National Cancer Institute Surveillance,
Epidemiology and End Results database to select all pathologically
proven stage IV M1b (TNM7) NSCLC patients (N= 39,655) diagnosed
between 2010 and 2015. Those with T0, M1a or M1 not otherwise
specified (without proven extrathoracic metastasis) were excluded.
Primary outcome was OS, secondary outcome was lung cancer specific
mortality (LCSM). Survival of patients with a primary tumor resection
(N=1,206 (3%), with 83.8% (bi)lobectomy), was compared with those
without primary tumor resection (N=38,449, the non-surgical group).
Survival of a propensity score matched (PSM) surgical and non-surgical
group (both N=315) was also compared. In the non-matched groups,
surgical patients had a more favourable clinical profile, with among
others significantly younger age, a lower T- and N-status, better dif-
ferentiated tumors, more often single-organ metastases and more often
also a metastasectomy compared to the non-surgical patients. In the
non-matched group, median OS was superior in the surgical group (14
versus 6 months, HR 0.49 (95% CI 0.46-0.52), p < 0.001). In the PSM
cohort, median OS remained superior (11 versus 7 months, HR 0.65
(95% CI 0.55-0.78), p < 0.001). Patients (N=644) referred for sur-
gery of the primary tumor, but not receiving surgery (without dying
before surgery), had a significantly worse median OS compared with
those that received surgery (6 versus 14 months, HR 0.46 (95% CI 0.41-
0.51), p < 0.001). In multivariate analysis, primary tumor resection
was independently associated with improved OS (HR 0.60; 95% CI
0.56-0.64, p < 0.001) in the whole cohort and in the surgery re-
commended cohort (HR 0.62; 95% CI 0.55-0.70, p < 0.001). For
LCSM, similar survival differences were found.
This is the first population-based analysis evaluating the benefit of
surgery for the primary tumor in stage IV M1b (TNM7) NSCLC. Even in
the metastatic setting, surgery improved the outcome of these patients
with lobectomy showing the most survival gain. What were the reasons
to offer surgery to these metastatic patients, and how where they se-
lected? And does this mean we should offer primary tumor surgery to
stage IV M1b patients, especially those with other good prognostic
factors such as low TN-status and single-organ metastases?
Patient characteristics were similar to a Dutch population based study
(N=11,094), evaluating survival in stage IV NSCLC in relation to number
of organs with metastases and TN-stage [12]. Percentage of single organ
metastases (59% vs 51%) and percentage of N0-1 disease (29.8% versus
31.6%) was comparable. Patients with single-organ metastases, especially
those with low TN-status (T1-2 and N0-1) had a superior OS compared to
those with metastases in two or more organs or with high TN-status (T3-4,
and/or N2-3). However, the median OS of single-organ metastases patients
with low TN-status was with 8.5 months lower than the median OS of the
patients with a resected primary tumor in the current analysis (14 months)
[12]. Interestingly, in the Dutch study, patients with a documented
18Fluodeoxyglucose positron emission tomography (18FDG-PET) had a su-
perior survival compared to those without (median 11.6 versus 8.2 months)
[12], which can be explained by the upstaging effects of 18FDG-PET (Will
Rogers phenomenon) [13]. In the present study, data on 18FDG-PET was not
available, although adequate imaging for stage IV patients eligible for LAT is
advised in the ESMO as well as the NCCN guidelines and in a recent
European Organisation for Research and Treatment of Cancer (EORTC)
statement [2,3,14]. It is possible that part of the survival differences at-
tributed to primary tumor surgery was caused by imbalances in extent of
staging. Furthermore, the current study only evaluated number of organs
with metastases, but did not specify number of metastases per organ. It is
known from the TNM8 data that number of extrathoracic metastases, even
within a single organ, is associated with survival [15].
Other questions that need to be answered before incorporating
primary tumor surgery into daily practice for stage IV NSCLC is how to
select patients, and whether LAT needs to be surgery. Adequate staging
is necessary, and selection of oligometastatic good performance status
patients with low TN-status, eligible for LAT seems best. In the current
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study, information on performance status is lacking and it is not clear
whether especially synchronous oligometastatic NSCLC patients or
oligoprogressive patients were treated with surgery of the primary,
making, despite the PSM, comparison of groups difficult. Furthermore,
definition of oligometastatic NSCLC varies [2,3,6,10]. A uniform defi-
nition is needed to design and compare clinical trials. The EORTC Lung
Cancer Group has recently proposed a consensus definition for syn-
chronous oligometastatic NSCLC [16]. Additionally, as only a small
percentage of oligometastatic patients obtains long-term survival with
LAT, better selection methods are needed. In the current study, 5-year
survival of patients with primary tumor surgery was 20%. It is possible
that integrated molecular subtyping can improve selection for LAT, as
in colorectal cancer this subtyping combined with a clinical risk stra-
tification was able to stratify patients into low, intermediate and high
risk groups, with clearly different survival [17].
Although not specifically addressed in the current study, a combi-
nation of local disease LAT plus LAT of all metastases is likely to pro-
vide more survival benefit than primary tumor LAT only. Indeed, both
ESMO and NCCN guidelines advise LAT of all visible disease in oligo-
metastatic patients [2,3]. It is unknown whether the patients in the
current study were also treated with LAT to other metastatic sites, as
26.9% underwent metastasectomy of at least one metastasis, but in-
formation on radiotherapy was not provided. It is possible that response
to induction systemic therapy is able to select patients with a better
prognosis that will probably have the most benefit of LAT. Cross-trial
comparison is difficult, but in the Gomez et al. trial, only patients re-
sponding to induction systemic treatment were treated with LAT:
median OS was 41.2 months [8]. In the single arm phase II trial of De
Ruysscher et al. almost all patients received systemic therapy but 54%
was treated with concurrent chemoradiotherapy: median OS was 13.5
months with a five-year survival of 7.7% [7]. The proportion of patients
receiving (induction) systemic treatment in the article of Sun et al. is
unknown. Asian race was associated with improved survival in this
study. These patients often have a targetable driver mutation [18] and
they have a superior survival compared to non-driver mutated patients
[19]. It is also possible that these patients received surgery because of
oligoprogression, as LAT is an accepted treatment method in oligo-
progressive driver mutated patients.
The reported phase II trials included only patients eligible for LAT to
the primary as well as the metastatic sites [6–8,10]. With the exception
of the Iyengar et al trial [6], choice of LAT was free. In the current
analysis, the authors did not evaluate whether SRT yielded results
comparable to surgery. In a recent systematic review and meta-analysis,
radiotherapy to the primary also improved survival in oligometastatic
(synchronous/metachronous) NSCLC [20]. Furthermore, immune
checkpoint inhibitors (ICI) have revolutionized the treatment strategies
for NSCLC. Radiotherapy and ICI act synergistically, while this is not
the case for surgery [21]. Therefore, it is possible that in the ICI era
radiotherapy is thought to be the preferred LAT technique.
In conclusion, the current study adds evidence to the statement that
LAT improves survival in a (selected, probably oligometastatic/oligo-
progressive) group of stage IV NSCLC patients. Accurate staging is es-
sential, and research should focus on how to select patients that benefit
most from LAT (e.g. the role of N2-N3 disease: this is evaluated in the
SARON trial (NCT 02417662)), the optimal type of LAT, and the role of
ICI (evaluated in for example NCT NCT02316002). To compare these
trials, a single oligometastatic definition is needed.
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